Checkpoint inhibitors have revolutionized cancer treatment, but they aren’t perfect, and there is a niche for therapies to treat those whose disease progresses despite receiving these therapies. Replimune Group Inc. believes its cancer vaccine RP1 (vusolimogene oderparepvec) could become the go-to option for melanoma patients in this situation following an impressive update from the IGNYTE trial.
ESMO 24: Replimune’s Cancer Vaccine Succeeds In PD-1 Failures
New data suggest that RP1 could become the therapy of choice in melanoma patients who do not respond to checkpoint inhibitors.
More from Clinical Trials
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
A decision from the FDA is due by 28 September.
• By
The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.